SCHEMBL2394622

SCHEMBL2394622

CC(=O)Cc1ccc(Cl)c(S(=O)(=O)NCCO)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 4/20 0.57
PIK3CD O00329 3/20 0.50
PIK3CG P48736 3/20 0.50
PI4KB Q9UBF8 2/20 0.50
PIK3C2A O00443 1/20 0.50
PIK3C2B O00750 1/20 0.50
PIK3CA P42336 1/20 0.50
PIK3CB P42338 1/20 0.50
PI4KA P42356 1/20 0.50
PRKDC P78527 1/20 0.50
PIK3C3 Q8NEB9 1/20 0.50
GAA P10253 1/20 0.47
F10 P00742 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
ALDH1A1 P00352 2/20 0.42
PDK1 Q15118 1/20 0.42
PDK2 Q15119 1/20 0.42
PDK3 Q15120 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13525273 0.88 GSTO1 (0.44) GSTO1PIK3CDPIK3CGPI4KBPIK3C2A
SCHEMBL29180147 0.86 GSTO1 (0.43) GSTO1PIK3CDPIK3CGPI4KBPIK3C2A
SCHEMBL29183496 0.85 POLB (0.43) GSTO1GAAF10PRSS1PRSS2
SCHEMBL3717918 0.78 GAA (0.67) GSTO1PIK3CDPIK3CGPI4KBPIK3C2A
SCHEMBL30792215 0.78 GSTO1 (0.41) GSTO1PIK3CAALDH1A1POLBL3MBTL1
SCHEMBL48608 0.78 GSTO1 (0.41) GSTO1PIK3CAALDH1A1POLBL3MBTL1
SCHEMBL48740 0.78 GSTO1 (0.41) GSTO1ALDH1A1POLBTDP1L3MBTL1
SCHEMBL3642110 0.77 ALDH1A1 (0.59) PIK3CDPIK3CGPIK3CAPIK3CBGAA
SCHEMBL2398831 0.77 CA1 (0.49)
SCHEMBL9321467 0.76 GSTO1 (0.60) GSTO1PIK3CDPIK3CGPI4KBPIK3C2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 GSTO1 4164/4885PIK3CD 42/4885PIK3CG 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.